NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Novo Nordisk (NVO) has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the candidate led to a statistically significant and superior weight loss at week 68 compared to placebo.CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness and helping individu ...